nybanner8

Pipeline

We build a world-class pipeline by proprietary discovery platforms. Our innovation engine has been validated by clinical assets and global partnerships.

Get in Touch →
You are here: Home » Pipeline
PHASE 3
Target / Modality: TSLP mAb
Indication: SA/COPD
Status: SA-Phase 3, AD-Phase 2
Partner(territory right): Aclaris (Global ex-China) CTTQ (China)
PHASE 3
Target / Modality: IL4R mAb
Indication: AD/CRSwNP
Status: AD/CRSwNP - Phase 3
Partner(territory right): CTTQ(Global)
PHASE 2
Target / Modality: TROP2-ADC
Indication: Gastric cancer/Cholangiocarcinoma
Status: Phase 1/2
Partner(territory right): OBI Pharma (Global ex-China)
PHASE 1
Target / Modality: TSLP x IL4R
Indication: AD/SA
Status: AD-Phase 1
Partner(territory right): Aclaris (Global ex-China)
PHASE 1
Target / Modality: Anti-Siglec-15 mAb
Indication: Oncology
Status: Phase 1
Partner(territory right): Pyxis Oncology (Global ex-China)
PHASE 1
Target / Modality: PD-1 x ILT4 bispecific
Indication: Oncology
Status: Phase 1
Partner(territory right): Celldex(Global ex-China)
PHASE 1
Target / Modality: HER2 (Novel Epitope)
Indication: Solid Tumors
Status: Phase 1
Partner(territory right): AnkeBio (China)
PHASE 1
Target / Modality: SIRPα mAb
Indication: Solid Tumors
Status: Phase 1 (IIT)
Partner(territory right): Available for partnerhip
PRE-CLINICAL
Target / Modality: BTN3A Agonist
Indication: AML
Status: IND filing 26Q4
Partner(territory right): Available for partnerhip
PRE-CLINICAL
Target / Modality: IL7R x IL4R
Indication: SA/AD/COPD
Status: IND filing 26Q3
Partner(territory right): Available for partnerhip
PRE-CLINICAL
Target / Modality: HER2 × PD-L1 bispecific ADC
Indication: Solid Tumors
Status: Pre-clinical
Partner(territory right): Available for partnerhip

Find us in China, Hong Kong SAR, the United States & Australia

Quick Links

Copyright © 2026 Biosion All Rights Reserved. | Sitemap | Privacy Policy